SPAIN - 2021/03/02: In this photo illustration a medical syringe seen displayed in front of the Novavax logo. (Photo Illustration by Thiago Prudêncio/SOPA Images/LightRocket via Getty Images) Novavax announced Monday it saw promising results in a preclinic study of a test shot that combines a vaccine for the seasonal flu and COVID-19.
Novavax, a Maryland-based biotechnology company that’s also been developing a standalone COVID-19 vaccine, said their combo shot formed a "robust response" to both influenza A and B as well as protected against SARS-CoV-2, the virus that causes COVID-19"We believe that this novel combination vaccine candidate, which leverages Novavax's technology platform and Matrix-M™ adjuvant, could be an important future.